In addition to drug repositioning against SOD2 anti-oxidative stress molecules and targeting RECQL1 and WRN to induce cancer-specific synthetic lethality, it is advisable to implement nucleic acid-based drugs, such as siRNA and antisense oligonucleotides, to treat OCCCs effectively and to adapt them to the transcriptional profile of individual tumor characteristics in the era of precision medicine. The gene discussed is RECQL; the disease is neoplasm.